FIGURE 3.

Ntf3 overexpression acutely increases ABR peak 1 amplitudes in middle‐aged mice but not in the young. (a) DPOAE and ABR recordings performed 1 week before and one week after tamoxifen injection at 60 weeks of age show that activation of Ntf3 overexpression in Ntf3 ^stop :Slc1a3/CreER ^T mice rapidly increases ABR peak 1 amplitudes without altering ABR and DPOAE thresholds. This does not occur in age‐matched Ntf3 ^stop control mice. (b) No Ntf3‐induced increases in ABR peak 1 amplitudes were seen when young adult (8‐week‐old) were tested. Suprathreshold ABR peak 1 amplitudes were analyzed at 80 dB SPL. Middle‐aged adults Ntf3 ^stop n = 11 mice; Middle‐aged Ntf3 ^stop :Slc1a3/CreER ^T n = 13–17 mice; Young adults Ntf3 ^stop n = 22 mice; Young adults Ntf3 ^stop :Slc1a3/CreER ^T n = 20 mice. 2‐way ANOVA followed by Sidak's multiple comparisons test was used to evaluate thresholds and amplitudes within each group before (baseline) and after tamoxifen treatment. ** p < 0.01. Error bars represent SEM